USE OF DISCRETE EVENT SIMULATION TO EVALUATE THE CLINICAL PRACTICES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

REAL J.P; LUNA J.D; PALMA SD

MEDICINA (BUENOS AIRES)

MEDICINA (BUENOS AIRES)

Lugar: Buenos Aires; Año: 2016 vol. 76 p. 212 - 212

0025-7680

eovascualar Age-related Macular Degeneration (nAMD) is the leading cause of severe visual loss in the developed world. Intravitreal anti vascular endothelial growth factors (anti-VEGFs) are effective but involve substantial resource burden.Since the initiation of anti-VEGF therapy, different treatment regimens have been developed attempting to provide comparable visual result,but with a fewer number of injections or visits. Purpose:To evaluate the outcomes and direct medical cost of different regimen treatments in managing nAMD. Methods:We developed a discrete event simulation model reproducing the long-term evolution of 5000 patients with nAMD. The model allows the calculation of the cost-effectiveness of treatment of AMD with two different therapeutic regimens: pro re nata (PRN) and Treat and Extend (TAE). The simulation was performed using 3 available drugs: Ranibizumab (RNB),Bevacizumab (BVZ) and Aflibercept (AFL). Data on effectiveness, rate of visual loss without treatment, the